(VIANEWS) – Jiayin Group (JFIN), Insulet (PODD), Semler Scientific (SMLR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Jiayin Group (JFIN)
136.4% sales growth and 106.77% return on equity
Jiayin Group Inc. operates as an online individual finance platform that connects individual investors and individual borrowers in China. It operates a secure and open platform that facilitates transparent, secure, and fast connections between investors and borrowers. The company was founded in 2011 and is based in Shanghai, the People's Republic of China.
Earnings Per Share
As for profitability, Jiayin Group has a trailing twelve months EPS of $3.84.
PE Ratio
Jiayin Group has a trailing twelve months price to earnings ratio of 1.35. Meaning, the purchaser of the share is investing $1.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 106.77%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jul 26, 2023, the estimated forward annual dividend rate is 0.4 and the estimated forward annual dividend yield is 7.25%.
Yearly Top and Bottom Value
Jiayin Group’s stock is valued at $5.17 at 04:22 EST, way under its 52-week high of $8.19 and way above its 52-week low of $1.86.
Sales Growth
Jiayin Group’s sales growth is negative 3.5% for the present quarter and 136.4% for the next.
2. Insulet (PODD)
23.6% sales growth and 23.18% return on equity
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Earnings Per Share
As for profitability, Insulet has a trailing twelve months EPS of $1.72.
PE Ratio
Insulet has a trailing twelve months price to earnings ratio of 114.29. Meaning, the purchaser of the share is investing $114.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.18%.
Yearly Top and Bottom Value
Insulet’s stock is valued at $196.57 at 04:22 EST, way under its 52-week high of $335.91 and way higher than its 52-week low of $125.82.
Previous days news about Insulet(PODD)
- According to Zacks on Monday, 11 December, "Some better-ranked stocks in the broader medical space are Haemonetics (HAE Quick QuoteHAE – Free Report) , Insulet (PODD Quick QuotePODD – Free Report) and DexCom (DXCM Quick QuoteDXCM – Free Report) . ", "Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). "
- According to Zacks on Monday, 11 December, "While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). "
- According to Zacks on Monday, 11 December, "Some better-ranked stocks in the broader medical space are Haemonetics (HAE Quick QuoteHAE – Free Report) , Insulet (PODD Quick QuotePODD – Free Report) and DexCom (DXCM Quick QuoteDXCM – Free Report) . ", "While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). "
- According to Zacks on Tuesday, 12 December, "Some better-ranked stocks in the broader medical space are Haemonetics (HAE Quick QuoteHAE – Free Report) , Insulet (PODD Quick QuotePODD – Free Report) and DexCom (DXCM Quick QuoteDXCM – Free Report) . ", "Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). "
3. Semler Scientific (SMLR)
21.9% sales growth and 31.8% return on equity
Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
Earnings Per Share
As for profitability, Semler Scientific has a trailing twelve months EPS of $2.5.
PE Ratio
Semler Scientific has a trailing twelve months price to earnings ratio of 18.02. Meaning, the purchaser of the share is investing $18.02 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.8%.
Moving Average
Semler Scientific’s value is way higher than its 50-day moving average of $33.20 and way higher than its 200-day moving average of $27.50.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 39% and 87.3%, respectively.
Volume
Today’s last reported volume for Semler Scientific is 66201 which is 18.86% above its average volume of 55696.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.2%, now sitting on 66.92M for the twelve trailing months.
4. Eli Lilly and Company (LLY)
19.8% sales growth and 46.46% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $5.55.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 104.56. Meaning, the purchaser of the share is investing $104.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 46.46%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Feb 13, 2024, the estimated forward annual dividend rate is 5.2 and the estimated forward annual dividend yield is 0.87%.
5. AvalonBay Communities (AVB)
13.5% sales growth and 8.07% return on equity
As of September 30, 2023, the Company owned or held a direct or indirect ownership interest in 296 apartment communities containing 89,240 apartment homes in 12 states and the District of Columbia, of which 17 communities were under development and one community was under redevelopment. The Company is an equity REIT in the business of developing, redeveloping, acquiring and managing apartment communities in leading metropolitan areas in New England, the New York/New Jersey Metro area, the Mid-Atlantic, the Pacific Northwest, and Northern and Southern California, as well as in the Company's expansion regions of Raleigh-Durham and Charlotte, North Carolina, Southeast Florida, Dallas and Austin, Texas, and Denver, Colorado.
Earnings Per Share
As for profitability, AvalonBay Communities has a trailing twelve months EPS of $6.58.
PE Ratio
AvalonBay Communities has a trailing twelve months price to earnings ratio of 26.83. Meaning, the purchaser of the share is investing $26.83 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.07%.
Volume
Today’s last reported volume for AvalonBay Communities is 235384 which is 69.1% below its average volume of 761826.
Moving Average
AvalonBay Communities’s value is above its 50-day moving average of $171.00 and under its 200-day moving average of $177.16.
6. Akamai Technologies (AKAM)
9.1% sales growth and 12.04% return on equity
Akamai Technologies, Inc. provides cloud services for securing, delivering, and computing content, applications, and software over the internet in the United States and internationally. The company offers cloud solutions to keep infrastructure, websites, applications, application programming interfaces, and users safe from various cyberattacks and online threats while enhancing performance. It also provides web and mobile performance solutions to enable dynamic websites and applications; media delivery solutions, including video streaming and video player services, game and software delivery, broadcast operations, authoritative domain name system, resolution, and data and analytics; and cloud computing services, such as compute, storage, networking, database, and container management services to build, deploy, and secure applications and workloads. In addition, the company offers carrier offerings, including cybersecurity protection, parental controls, DNS infrastructure and content delivery solutions; and an array of service and support to assist customers with integrating, configuring, optimizing, and managing its offerings. It sells its solutions through direct sales and service organizations, as well as through various channel partners. The company was incorporated in 1998 and is headquartered in Cambridge, Massachusetts.
Earnings Per Share
As for profitability, Akamai Technologies has a trailing twelve months EPS of $3.32.
PE Ratio
Akamai Technologies has a trailing twelve months price to earnings ratio of 34.77. Meaning, the purchaser of the share is investing $34.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.04%.
Yearly Top and Bottom Value
Akamai Technologies’s stock is valued at $115.43 at 04:22 EST, under its 52-week high of $116.88 and way above its 52-week low of $70.65.
Volume
Today’s last reported volume for Akamai Technologies is 291178 which is 81.79% below its average volume of 1599090.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 16.1% and 13.6%, respectively.
